Laso Lab Limited is a company incorporated and registered in United Kingdom with company number 10875538. The registered office is The Station Masters’ House 168 Thornbury Road, Osterley Village, Isleworth, Middlesex, United Kingdom, TW7 4QE.
LasoLab was established in 2017 with lab space at Reading University in the United Kingdom, at which time Laso Lab engaged with scientists at Reading University to conduct supramolecular clinical research relating to the health benefits of specific plants.
LasoLab’s research will enable the extraction, purification and chemical functional characterisation of active pharmaceutical ingredient (API) with medicinal properties in particular to promote novel means of beneficial treatments through a small-scale extraction protocol which will feed into a platform for efficacy testing. Once Laso Lab has established a defined condition for the extraction and purification of API(s), Laso Lab will then scale up the process, which will feed into a molecular characterisation process to determine the identity of the API(s).
LasoLab oversees fully vertical operations in the CBD Health and Wellness with seed-to-shelf cultivation, processing, international distribution and fulfillment assets spanning North America, serving the world.
LasoLab’s experienced team specializes in identifying, evaluating and securing assets based on their value, talent and potential. While Laso follows the traditional model of other CBD and Wellness companies that look for current and potential value through a financial lens, Laso relies on its deep understanding of the market to go a step further by seeking out partnerships that will bring the best talent, knowledge, and experience to its partnership network.
The Laso process for evaluating partner acquisitions looks to immediate term profitability and net asset value, as well as positioning for leadership in the evolution of the CBD Wellness ecosystem.
CBD is a non-psychoactive cannabinoid offering Wellness effects for many medical indications including pain, anxiety and epilepsy. As such, significant opportunities exist for mass commercialization of CBD products. A wide range of potential applications (from nutritional supplements to pet food) will propel hemp-derived CBD products into mass market retailers in the coming years.